Breaking News Instant updates and real-time market news.

ARNA

Arena Pharmaceuticals

$24.29

0.22 (0.91%)

, VLRX

Valeritas

$3.50

0.24 (7.36%)

04:55
09/15/17
09/15
04:55
09/15/17
04:55

European Association for the Study of Diabetes to hold annual meeting

53rd Annual Meeting of EASD 2017 is being held in Lisbon, Portugal on September 11-15.

ARNA

Arena Pharmaceuticals

$24.29

0.22 (0.91%)

VLRX

Valeritas

$3.50

0.24 (7.36%)

VTVT

vTv Therapeutics

$5.37

-0.05 (-0.92%)

  • 15

    Sep

  • 25

    Sep

  • 26

    Sep

ARNA Arena Pharmaceuticals
$24.29

0.22 (0.91%)

06/27/17
06/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Alex Yao resumed coverage of Alibaba (BABA) Group with an Overweight rating and $190 price target following a period of restriction. The rating is unchanged and the price target is raised from $140. 2. SunTrust analyst Terry Tillman initiated Salesforce (CRM) with a Buy and a $110 price target and views its as a core holding for large-cap investors. 3. Citi analyst Joel Beatty started Arena Pharmaceuticals (ARNA) with a Buy rating and $23 price target. 4. Deutsche Bank analyst Bryan Kraft started Lionsgate Class A (LGF.A) shares with a Hold rating and $29 price target. 5. Cantor Fitzgerald analyst Louise Chen assumed coverage of Amarin (AMRN) with an Overweight rating and $10 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/17
LEER
07/11/17
NO CHANGE
Target $53
LEER
Outperform
Arena Pharmaceuticals price target raised to $53 from $47 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Arena Pharmaceuticals to $53 from $47 after the company reported "promising" topline results from its Phase 2 ralinepag study in pulmonary arterial hypertension that surpassed the benchmark established by its competitor selexipag. On the heels of ralinepag data, the analyst believes investors will begin to assign greater value to the company's proprietary pipeline that could present further upside in not only mass-market indications like ulcerative colitis and pain, but also in the rare manifestations including pyoderma gangrenosum and extraintestinal manifestations. Schwartz reiterates an Outperform rating on the shares.
07/11/17
JMPS
07/11/17
NO CHANGE
JMPS
Arena Pharmaceuticals price target raised to $36 from $27 at JMP Securities
JMP Securities analyst Jason Butler says that the Phase 2 results of Arena's Ralinepag in PAH indicates that it has "a compelling clinical profile" that supports "a blockbuster commercial opportunity." The analyst adds that the drug can become "the best-in-class oral prostacyclin receptor agonist." He raised his price target on the shares to $36 from $27 and keeps an Outperform rating on the stock.
07/11/17
SBSH
07/11/17
NO CHANGE
Target $37
SBSH
Buy
Arena Pharmaceuticals price target raised to $37 from $23 at Citi
VLRX Valeritas
$3.50

0.24 (7.36%)

07/10/17
WEDB
07/10/17
INITIATION
Target $12
WEDB
Outperform
Valeritas initiated with an Outperform at Wedbush
Pre-open, Wedbush analyst Tao Levy initiated Valeritas with an Outperform and a $12 price target telling investors the company is well positioned to increase adoption of its V-Go platform, a wearable insulin delivery device, after recently raising additional capital and completing a significant adjustment in its commercialization strategy.
04/17/17
COWN
04/17/17
INITIATION
COWN
Outperform
Valeritas initiated with an Outperform at Cowen
Cowen analyst Doug Schenkel initiated Valeritas with an Outperform saying its revamped commercial strategy under a different management structure has yielded promising early results. The analyst believes Valeritas has a differentiated insulin pump specifically for Type 2 patients within a $2-3B+ US TAM, and at a $100MM enterprise value, there could be material upside if management executes relative to expectations in 2017 and beyond.
09/27/16
RILY
09/27/16
INITIATION
Target $7.5
RILY
Buy
Valeritas initiated with a Buy at B. Riley
B. Riley analyst Greg Chodaczek started Valeritas with a Buy rating and $7.50 price target.
VTVT vTv Therapeutics
$5.37

-0.05 (-0.92%)

09/26/16
HCWC
09/26/16
INITIATION
Target $13
HCWC
Buy
vTv Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started vTv Therapeutics with a Buy rating and $13 price target.
12/15/16
HCWC
12/15/16
NO CHANGE
Target $13
HCWC
Buy
vTv Therapeutics Phase 2 diabetes data a 'big win,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis views vTv Therapeutics' (VTVT) data from its Phase 2 study of TTP273 in type-2 diabetes as "very positive" and a "big win." Efficacy is close to Novo Nordisk's (NVO) oral semaglutide, Davis tells investors in a research note. vTv is "highly likely" to succeed in finding a partner given the attractiveness of the diabetes market and the differentiated profile '273 has now created, the analyst contends. Davis keeps a Buy rating on the shares with a $13 price target.
12/15/16
STFL
12/15/16
NO CHANGE
STFL
vTv Therapeutics price target raised to $14 from $12 at Stifel
Stifel analyst Thomas Shrader believes that vTv's TTP273 showed positive results in a Phase IIb trial of T2d patients. The analyst thinks that the drug " has demonstrated proof of concept with hints of an improved safety profile relative to Byetta." He predicts that vTv will obtain a partner for the drug and will receive " a $100M - $200M upfront payment and low double digit royalties on sales." Shrader keeps a Buy rating on the shares.
03/29/17
STFL
03/29/17
NO CHANGE
Target $14
STFL
Buy
vTv Therapeutics TTP399 safety data looked 'very promising,' says Stifel
Stifel analyst Thomas Shrader said the safety data from vTv Therapeutics' Phase 2 trial of TTP399 looked "very promising" and appear to him to be "strong enough" to drive a partnership, which is likely required for the next stages of the drug's development. Shrader keeps a Buy rating and $14 price target on vTv shares.

TODAY'S FREE FLY STORIES

DSW

DSW

$20.89

0.26 (1.26%)

10:06
01/17/18
01/17
10:06
01/17/18
10:06
Conference/Events
DSW management to meet with Jefferies »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

10:04
01/17/18
01/17
10:04
01/17/18
10:04
Hot Stocks
Exact Sciences drops after release of abstract on possible Cologuard competitor »

Early weakness in shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 26

    Feb

VMW

VMware

$132.75

0.61 (0.46%)

10:02
01/17/18
01/17
10:02
01/17/18
10:02
Conference/Events
VMware management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 19

    Jan

GS

Goldman Sachs

$252.90

-5.33 (-2.06%)

10:01
01/17/18
01/17
10:01
01/17/18
10:01
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs »

Goldman Sachs CFO:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

BAH

Booz Allen

$40.02

0.16 (0.40%)

10:01
01/17/18
01/17
10:01
01/17/18
10:01
Hot Stocks
Booz Allen awarded $165M 5-year contract to support USCYBERCOM »

the General Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CMTL

Comtech

$21.40

-0.58 (-2.64%)

10:01
01/17/18
01/17
10:01
01/17/18
10:01
Hot Stocks
Comtech receives $19.1M follow-on contract »

Comtech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:01
01/17/18
01/17
10:01
01/17/18
10:01
General news
Housing Market Index data reported »

January Housing Market…

ACLS

Axcelis

$30.30

1.15 (3.95%)

, AMAT

Applied Materials

$54.50

1.05 (1.96%)

10:00
01/17/18
01/17
10:00
01/17/18
10:00
Recommendations
Axcelis, Applied Materials analyst commentary  »

Axcelis lowered margin…

ACLS

Axcelis

$30.30

1.15 (3.95%)

AMAT

Applied Materials

$54.50

1.05 (1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

FAST

Fastenal

$55.44

-0.15 (-0.27%)

10:00
01/17/18
01/17
10:00
01/17/18
10:00
Options
Fast action in Fastenal Feb 55s post earnings »

Fast action in Fastenal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

GS

Goldman Sachs

$253.61

-4.855 (-1.88%)

10:00
01/17/18
01/17
10:00
01/17/18
10:00
Hot Stocks
Goldman CFO: Trading facing 'low volatility, low activity' world »

CFO Marty Chavez said on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

MVC

MVC Capital

$10.70

-0.02 (-0.19%)

09:59
01/17/18
01/17
09:59
01/17/18
09:59
Conference/Events
MVC Capital management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

KEYW

KEYW

$6.46

0.09 (1.41%)

09:58
01/17/18
01/17
09:58
01/17/18
09:58
Conference/Events
KEYW management to meet with RBC Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 21

    Feb

  • 22

    Feb

  • 14

    Jun

RIOT

Riot Blockchain

$18.28

-3.6 (-16.45%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Options
Riot Blockchain Inc put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

LRCX

Lam Research

$190.39

1.88 (1.00%)

, MNST

Monster Beverage

$64.56

0.79 (1.24%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Options
Early notable gainers among liquid option names on January 17th »

Notable gainers among…

LRCX

Lam Research

$190.39

1.88 (1.00%)

MNST

Monster Beverage

$64.56

0.79 (1.24%)

IBM

IBM

$167.92

4.07 (2.48%)

IFF

International Flavors

$155.52

2.98 (1.95%)

KLAC

KLA-Tencor

$107.66

0.37 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 25

    Jan

DIS

Disney

$110.92

0.23 (0.21%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Periodicals
Disney's 'Last Jedi' drops 92% in second weekend at Chinese box office, THR says »

Disney's "Star…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 06

    Feb

AMZN

Amazon.com

$1,304.86

-0.34 (-0.03%)

, HD

Home Depot

$197.20

0.89 (0.45%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Conference/Events
Wedbush retail/hardlines analyst holds an analyst/industry conference call »

Retail/Hardlines Analyst…

AMZN

Amazon.com

$1,304.86

-0.34 (-0.03%)

HD

Home Depot

$197.20

0.89 (0.45%)

LOW

Lowe's

$101.01

0.0371 (0.04%)

W

Wayfair

$84.68

0.18 (0.21%)

WSM

Williams-Sonoma

$54.02

0.17 (0.32%)

BBBY

Bed Bath & Beyond

$23.01

0.19 (0.83%)

TPX

Tempur Sealy

$63.72

-0.075 (-0.12%)

AZO

AutoZone

$780.00

-1.02 (-0.13%)

AAP

Advance Auto Parts

$114.60

0.703 (0.62%)

ORLY

O'Reilly Automotive

$257.89

-0.71 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 08

    Feb

  • 18

    Feb

  • 20

    Feb

  • 22

    Feb

  • 18

    Mar

FB

Facebook

$178.39

-0.98 (-0.55%)

, TWTR

Twitter

$24.52

-0.14 (-0.57%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Committee holds a…

FB

Facebook

$178.39

-0.98 (-0.55%)

TWTR

Twitter

$24.52

-0.14 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

MRK

Merck

$62.32

0.25 (0.40%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Conference/Events
Leerink pharmaceuticals analysts hold an analyst/industry conference call »

Analysts discuss whether…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 23

    Oct

OPGN

OpGen

$0.19

0.0143 (8.29%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Conference/Events
OpGen to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

09:54
01/17/18
01/17
09:54
01/17/18
09:54
General news
Market opens with gains, but holding them will be the focus »

Stock futures were higher…

ACLS

Axcelis

$30.30

1.15 (3.95%)

09:53
01/17/18
01/17
09:53
01/17/18
09:53
Hot Stocks
Breaking Hot Stocks news story on Axcelis »

Axcelis drops 5% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

XLF

Financial Select Sector

$29.16

0.01 (0.03%)

, XLE

Energy Select Sector SPDR

$76.69

0.25 (0.33%)

09:52
01/17/18
01/17
09:52
01/17/18
09:52
Technical Analysis
Technical Take: S&P 500 moves moderately higher, sector breadth mixed »

The S&P 500 (SPX) was…

XLF

Financial Select Sector

$29.16

0.01 (0.03%)

XLE

Energy Select Sector SPDR

$76.69

0.25 (0.33%)

XLI

Industrial Select Sector SPDR

$79.59

0.14 (0.18%)

XLK

Technology Select Sector SPDR

$66.91

0.36 (0.54%)

XLP

Consumer Staples Sector SPDR

$57.23

0.32 (0.56%)

XLV

Health Care Select Sector SPDR

$87.53

0.28 (0.32%)

SPY

SPDR S&P 500 ETF Trust

$277.86

0.89 (0.32%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QADB

QAD Inc

$31.80

0.05 (0.16%)

09:50
01/17/18
01/17
09:50
01/17/18
09:50
Hot Stocks
Breaking Hot Stocks news story on QAD Inc 

QAD Inc trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITIC

Investors Title Company

$199.00

3.26 (1.67%)

09:50
01/17/18
01/17
09:50
01/17/18
09:50
Hot Stocks
Breaking Hot Stocks news story on Investors Title Company »

Investors Title Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$57.07

0.16 (0.28%)

09:45
01/17/18
01/17
09:45
01/17/18
09:45
Technical Analysis
Technical Take: Consumer Staples Sector SPDR nearing breakout »

The Consumer Staples…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.